Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Vaiheen I koe tiheyden tiheyden theta-purskeen stimulaatiosta (HDTBS)

maanantai 16. marraskuuta 2026 päivittänyt: National Institute on Drug Abuse (NIDA)

Vaiheen I kliininen tutkimus transkraniaalisen magneettisen stimulaation (TMS) turvallisuuden ja jälkähokausten tutkimiseksi käyttämällä korkean tiheyden teeta-purske stimulaation (HDTBS) paradigmaa

Background:

Transcranial magnetic stimulation (TMS) uses magnetic pulses to affect brain activity. A type of TMS called theta burst stimulation (TBS) is approved to treat people with major depression. Researchers have developed a new form of TBS called high-density TBS (hdTBS). They hope hdTBS will work better than TBS. But first they need to test the new treatment in healthy adults.

Objective:

To test hdTBS in healthy adults. Also, to compare the aftereffects of hdTBS and TBS.

Eligibility:

Healthy adults aged 22 to 60 years.

Design:

This is a multi-site study conducted at the Biomedical Research Center, National Institute on Drug Abuse Intramural Research Program in Baltimore, Maryland and Olin Neuropsychiatry Research Center in Hartford, Connecticut.

Participants will have 4 clinic visits over about 3 to 4 weeks. They must abstain from drugs and alcohol and limit caffeine before visits.

At their first visit, participants will be oriented to TBS. They will wear a cap and earplugs. A device with round coils will be placed near their head. When a brief electric current passes through the coil, it generates a magnetic pulse that stimulates the brain. Participants may feel a pulling sensation on the skin under the coil. Their fingers may move involuntarily.

At their next 3 visits, participants will receive either TBS or sham TBS. A sham TBS uses a low magnetic field to minimize the effects of the treatment. Participants will have up to 9 electrodes placed on 1 arm. These electrodes will measure the electrical activity in their muscles. Each TBS session will be videotaped.

At every visit, participants will answer questions about their health, including substance use. They will perform 2 tasks to test their thinking skills. They will perform a test on a computer to test their reaction time....

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Yksityiskohtainen kuvaus

Study Description:

This study is intended to test the safety and potential efficacy of the high density theta burst stimulation (hdTBS) paradigm. We hypothesize that hdTBS i) can be safely administered to normal healthy human subjects, and ii) can produce stronger and longer-lasting after-effects than the conventional FDA-approved TBS paradigm.

Objectives:

Primary Objective:

To determine whether hdTBS at the power level of 60% and 80% resting motor threshold can be safely administered to normal healthy human participants.

Secondary Objective:

To determine whether hdTBS produces stronger and longer-lasting after-effects than the conventional, FDA-approved TBS protocol. Here "after-effects" are defined as alterations in cortical excitability after TMS administration, which can be quantitatively assessed by measuring motor-evoked potential (MEP) before and after an acute session of TMS on the primary motor cortex. Changes in the characteristics and durations of the MEP signal relative to pre-TMS baseline reflect neuromodulation effects of the TMS session.

Endpoints:

Primary Endpoint:

Clinically significant adverse events as collected on the Noninvasive Brain Stimulation (NIBS) monitoring questionnaire and evaluated by the MAI in combination with the serious adverse event reports.

Secondary Endpoints:

20 complete datasets at the 80% RMT hdTBS dose that are evaluable for after-effects of hdTBS.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

40

Vaihe

  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Kimberly C Slater
  • Puhelinnumero: (667) 312-5287
  • Sähköposti: kmodo@nih.gov

Opiskelupaikat

    • Connecticut
      • Hartford, Connecticut, Yhdysvallat, 06106
        • Olin Neuropsychiatry Research Center
        • Ottaa yhteyttä:
    • Maryland
      • Baltimore, Maryland, Yhdysvallat, 21224
        • National Institute on Drug Abuse
        • Ottaa yhteyttä:
          • Kimberly Slater, B.A.
          • Puhelinnumero: 667-312-5287
          • Sähköposti: kmodo@nih.gov

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

22 vuotta - 60 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Be 22-60 years of age.

    --Justification: Many neural processes change with age, and these changes could introduce unwanted variability in behavior. In addition, the risk of difficult-to detect medical abnormalities such as silent cerebral infarcts increase with age. Children under the age of 22 are excluded from this study because safety of rTMS in children has not been studied. In addition, this study is more than minimal risk and presents no direct benefit.

  • Ability and willingness to provide written informed consent.

    • Justification: At NIH/NIDA, written informed consent must be obtained for this study per NIH policy and federal regulations. At pSites, written informed consent must be obtained per applicable local institutional policy and regulations and as described in the pSite addendum.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Pregnancy, intention to become pregnant, or individuals capable of becoming pregnant who are sexually active and unwilling to use a highly effective method of contraception.

    --Justification: it is unknown whether TMS poses a risk to fetuses.

  • Personal history of stroke, brain lesions, previous neurosurgery, any personal history of seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than two days or other neurological condition deemed by the MAI to be likely to affect response to the TBS being delivered.

    --Justification: Stroke or head trauma can lower the seizure threshold and are therefore contra-indications for TMS. Fainting episodes or syncope of unknown cause could indicate an undiagnosed condition associated with seizures.

  • Acute, unstable cardiac disease, history of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or any heart condition currently under medical care.

    --Justifications: the risk of TMS for individuals with a heart condition is unknown.

  • Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps, intracardiac lines, intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object in the body that precludes TMS intervention.

    --Justification: Any metal around the head is a contraindication for TMS, as it involves exposure to a relatively strong magnetic field.

  • First-degree family history of any form of epilepsy with a potentially hereditary basis.

    --Justification: First-degree family history of epilepsy with a hereditary component increases the risk of the participant having an undiagnosed condition that is associated with lowered seizure threshold.

  • Current use (generally, any use in the past 4 weeks or chronic use within 6 past six months) of any investigational drug or of any medications with psychotropic, anti or pro-convulsive action. The MAI retains final discretion.

    --Justification: The use of certain medications or drugs can lower seizure threshold and is therefore contraindicated for TMS.

  • Otherwise TMS incompatible or have participated in any noninvasive brain stimulation (NIBS) session in the past two weeks or a NIBS treatment course in a clinical setting in the past 6 months.

    --Justification: in order to limit exposure to TMS, we will not enroll participants who have received TMS less than two weeks ago.

  • Noise-induced hearing loss (with or without or tinnitus), and/or tinnitus requiring treatment or that is severe, unstable, or otherwise clinically significant. Participants with mild tinnitus unrelated to hearing loss may be enrolled at the MAI's discretion.

    --Justification: individuals with noise-induced hearing problems may be particularly vulnerable to the acoustic noise generated by TMS equipment.

  • Lifetime history of schizophrenia, bipolar disorder, mania, hypomania, learning disability with accommodation or moderate or severe ADHD (as indicated by history of special accommodations/special education classes and/or medication for the majority of K-12 education). Recent history (within past 12 months) of major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder or PTSD that is symptomatic and/or on medication in the last 12 months, or mild ADHD on medication. Exclusion for mental health conditions will be determined at the discretion of the MAI.

    --Justification: The population of interest here is a healthy control population with no psychiatric disorders. In participants with depression, bipolar disorder, mania or hypomania, there is a small chance that TMS can trigger (hypo)manic symptoms.

  • Meet current or past DSM-5 criteria for any substance use disorder, or urine toxicology positive for any illicit substance including THC inconsistent with history given.

    --Justification: The population of interest is a healthy control population with no present or past substance use disorder. Current use of illicit substances could lower seizure threshold and is therefore contraindicated for TMS.

  • Current use of nicotine (self-report, urine cotinine test and/ or CO consistent with smoker) or history of more than 20 cigarettes or 20 instances of nicotine use in lifetime or history of daily nicotine use.

    --Justification: The population of interest here is a healthy control population with no substance use disorder and therefore a minimal nicotine exposure history in the control group is required.

  • Current regular use of more than 2 cups of coffee or equivalent caffeine intake in the morning (not total daily intake).

    --Justification: Excessive caffeine use can reduce seizure threshold and could potentially increase risk of TMS-induced seizure.

  • Any other condition that in the judgment of the investigators is incompatible with participation

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Satunnaistettu
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: Active TBS (3- and 5-pulse TBS)

Each participant will receive 2 active TBS (3- and 5-pulse TBS) and 1 sham TBS on 3 visits separated by at least 48 hours to minimize any potential accumulating effects from prior visits.

TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.

Each subject will receive 2 active TBS (3- and 5-pulse TBS) and 1 sham TBS on 3 visits separated by at least 48 hours.

Huijausvertailija: Sham TBS

Each participant will receive 2 active TBS (3- and 5-pulse TBS) and 1 sham TBS on 3 visits separated by at least 48 hours to minimize any potential accumulating effects from prior visits.

TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.

Each subject will receive 2 active TBS (3- and 5-pulse TBS) and 1 sham TBS on 3 visits separated by at least 48 hours.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Clinically significant adverse events as collected on the Noninvasive Brain Stimulation (NIBS) monitoring questionnaire and evaluated by the MAI in combination with the serious adverse event reports.
Aikaikkuna: about 3-4 weeks

As a phase I trial, 25 participants are a reasonable sample size for a preliminary assessment of the safety profile of the hdTBS paradigm.

about 3-4 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
20 complete datasets at the 80% RMT hdTBS dose that are evaluable for after-effects of hdTBS.
Aikaikkuna: about 3-4 weeks

20 complete datasets should give sufficient power to detect an effect. hdTBS produces stronger and longer lasting after-effects sets a solid foundation for future study in patients to investigate the efficacy of the new TMS paradigm.

about 3-4 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Yihong Yang, Ph.D., National Institute on Drug Abuse (NIDA)

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Sunnuntai 22. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 13. tammikuuta 2028

Opintojen valmistuminen (Arvioitu)

Torstai 13. tammikuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 10. maaliskuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 10. maaliskuuta 2025

Ensimmäinen Lähetetty (Todellinen)

Tiistai 11. maaliskuuta 2025

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 16. marraskuuta 2026

Viimeksi vahvistettu

Maanantai 21. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

We share information with researchers outside the NIH in two ways. Most commonly, we have specific partnerships with other researchers. Also, we may put data into one or more scientific databases, where it is stored along with information from other studies. Researchers can then study the information combined from many studies to learn even more about health and disease. We will share some protocol data with our scientific research partners inside or outside the NIH. Research partners outside the NIH sign an agreement with the NIH to share data. This agreement indicates the type of data that can be shared and what can be done with those data.@@@Additionally, de-identified data may be shared with properly administered databases and/or with collaborators with whom proper data sharing agreements are in place, after consultation with and approval from the NIDA-IRP Scientific Director.

IPD-jaon aikakehys

Data will be made available at the time of publication and as long as the archive is online or for a minimum of 5 years after publication in the event it must be moved to new hosting archives.

IPD-jaon käyttöoikeuskriteerit

We may put data into one or more scientific databases, where it is stored along with information from other studies. We will share some protocol data with our scientific research partners inside or outside the NIH. Research partners outside the NIH sign an agreement with the NIH to share data. This agreement indicates the type of data that can be shared and what can be done with those data.@@@Additionally, de-identified data may be shared with properly administered databases and/or with collaborators with whom proper data sharing agreements are in place, after consultation with and approval from the NIDA-IRP Scientific Director. Data shared with NIH investigators outside of NIDA, unless otherwise stated, would be sent by NIDA as de-identified data via secure email, encryption or secured ftp. The code to those data will not be shared.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF
  • ANALYTIC_CODE
  • CSR

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Joo

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa